Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of EGFR-driven cancer with fewer side effects

Treatment of EGFR-driven cancer with fewer side effects

US Patent 11395821 · Granted Jul 26, 2022

Estimated economic value: $5,768,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Morphic forms of trilaciclib and methods of manufacture thereof2025
Morphic forms of trilaciclib and methods of manufacture thereof2025
G1T38 superior dosage regimes2025
G1T38 superior dosage regimes2025
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Morphic forms of trilaciclib and methods of manufacture thereof2024
Transient protection of normal cells during chemotherapy2023
Transient protection of normal cells during chemotherapy2023
HSPC-sparing treatments for RB-positive abnormal cellular proliferation2023